Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Kg

Bi Pharma Kg.

Michael Trunk

Michael Walz

Hagen Graebner

Peter Sieger

Dieter Hochrainer

Rolf Banholzer

Burkhard Metzger

Helmut Meissner

Andreas Mathes

Peter Specht

Michael Krueger

Joerg Schiewe

Karoline Bechtold-Peters

Manfred Graulich

Bernd Wilhelm Mueller

Christian Kulinna

Konrad Schindler

Helmut Bender

Inga-Lis Timmermann

Hartwig Andreas Steckel

Mareke Hartig

Friedrich Schmidt

Claudius Weiler

Norbert Rasenack

Werner Pieroth

Manfred Ludwig Graulich

Thomas Weuthen

Mareke Hartig-Heimel

Stephanie Ossadnik

Nobert Rasenack

Hartig-Heimel Mareke

The invention relates to a method for producing a micronized, virtually anhydrous form of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane bromide, said form per se, and the use thereof for producing a medicament, especially a medicament having an anticholinergic effect.

Micronization method

The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

Encapsulated tiotropium containing powder formulation for inhalation

Tiotropium containing powder formulation for inhalation

The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention.

Powdered inhalants based on modified lactose mixtures as excipient

The invention relates to a process for the surface-energy passivation of lactose which is intended for use as an excipient in the production of inhalable powders, and the use of such optimised carrier materials in the manufacture of inhalable powders.

Surface modification of lactose excipient for use in powders for inhalation

The invention relates to a crystalline micronisate of (1 &#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.

Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament

Anticholinergic powder formulations for inhalation

The invention relates to a crystalline micronisate of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.

Crystalline monohydrate of (1&#x3b1;,2&#x3b2;,4&#x3b2;,5&#x3b1;,7&#x3b2;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions

The invention relates to salts of the active substance base 1-[N-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.

Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them

Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-&lsqb;(hydroxydi-2-thienylacetyl)oxy&rsqb;-9,9-dimethyl-3-oxa-9-azoniatricyclo&lsqb;3.3.1.0 &rsqb;nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.

Growing community of inventors

Ingelheim, Germany

Michael Trunk